Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
ORLADEYO 150MG CAPS is a federal award for 260-Network Contract Office 20 (36C260) held by Biocryst Pharmaceuticals, Inc. Estimated value $202K ($202K obligated). Current period of performance ends Oct 4, 2024. Last award drew 1 bidder. Place of performance: EARTH CITY MO.
Recompete timing
PublicCurrent PoP ended Oct 4, 2024 (686 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C26024F0258?
36C26024F0258 (Orladeyo 150mg CAPS) is a 260-Network Contract Office 20 (36C260) award with a potential value of $202K, currently held by Biocryst Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C260-24-F-0258?
36C260-24-F-0258 is the dashed form of PIID 36C26024F0258 (Orladeyo 150mg CAPS), held by Biocryst Pharmaceuticals, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C26024F0258?
260-Network Contract Office 20 (36C260) awarded 36C26024F0258 to Biocryst Pharmaceuticals, Inc (potential $202K).
Who is the incumbent on 36C26024F0258?
Biocryst Pharmaceuticals, Inc is the incumbent. The current period of performance ends Oct 4, 2024.
When does Biocryst Pharmaceuticals, Inc’s 36C26024F0258 come up for recompete?
SCOUT tracks a period-of-performance end of Oct 4, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.